Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia

BACKGROUND: Thrombocytopenia in patients with myelodysplastic syndrome (MDS) is associated with shortened survival and an increased risk of evolution to acute myeloid leukemia (AML). In this study, the authors evaluated the efficacy of romiplostim in patients who had thrombocytopenia with low-risk/i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer
Hlavní autoři: Giagounidis, Aristoteles, Mufti, Ghulam J, Fenaux, Pierre, Sekeres, Mikkael A, Szer, Jeffrey, Platzbecker, Uwe, Kuendgen, Andrea, Gaidano, Gianluca, Wiktor-Jedrzejczak, Wieslaw, Hu, Kuolung, Woodard, Paul, Yang, Allen S, Kantarjian, Hagop M
Médium: Artigo
Jazyk:Inglês
Vydáno: BlackWell Publishing Ltd 2014
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4298760/
https://ncbi.nlm.nih.gov/pubmed/24706489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28663
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky